ABBV - AbbVie navitoclax Jakafi combo shows promise in trial to treat rare bone marrow cancer

AbbVie (NYSE:ABBV) said new data from a mid-stage trial suggest that eraly intervention in patients with myelofibrosis (MF) with navitoclax in combination with Incyte's (INCY) Jakafi led to improved outcomes. The company presented data from group 3 of a phase 2 trial, dubbed REFINE, of navitoclax in combination with Jakafi (ruxolitinib) to treat patients with MF who have not received a prior therapy with a JAK inhibitor,  MF is a rare type of bone marrow cancer which disrupts body's normal production of blood cells. The phase 2 trial is evaluating the safety and efficacy of navitoclax alone or in combination with ruxolitinib in MF. The main goal in the cohort 3, which included 32 JAK inhibitor naïve patients with MF,  was was spleen volume reduction of ?35% (SVR35) from baseline at week 24 The company said spleen volume reduction of ?35% was achieved by 63% (20/32) of patients at week-24, and by 78%, or 25

For further details see:

AbbVie navitoclax, Jakafi combo shows promise in trial to treat rare bone marrow cancer